First-line treatment for symptomatic benign prostatic hyperplasia: Is there a particular patient profile for a particular treatment?

World Journal of Urology

Volumn 24, Issue 4, 2006, Pages 360-366

  Gonzalez, Ricardo R ^a   Kaplan, Steven A ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Antimuscarinic agents; BPH; LUTS; Medical therapy; Phosphodiesterase inhibitors; Prostatectomy

Indexed keywords

ARTICLE; HUMAN; MALE; PROSTATE HYPERTROPHY;

HUMANS; MALE; PROSTATIC HYPERPLASIA;

EID: 33748118770     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-006-0092-0     Document Type: Article

References (37)

1. de la Rosette JJMCH, Alivizatos G, Madersbacher S, Peracchino M, Thomas D, Degrandchamps F, de Wildt M (2001) EAU guidelines on benign prostatic hyperplasia (BPH). Eur Urol 40:256-263
2. AUA Practice Guidelines Committee (2003) AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol 170:530-547. http://www.auanet.org/guidelines/ bph.cfm
3. Ball AJ, Feneley RCL, Abrahams PH (1981) The natural history of untreated 'prostatism'. Br J Urol 53:613-616
4. Lepor H, Gup DI, Baumann M et al (1988) Laboratory assessment of terazosin and alpha-1 blockade in prostatic hyperplasia. Urology 32(6):21-26
5. Narayan P, Tewari A (1998) Overview of alpha-blocker therapy for benign prostatic hyperplasia. Urology 51(4A):38-45
6. Wilson JD (1980) The pathogenesis of benign prostate hyperplasia. Am J Med 68:745-756
7. Walsh PC, Madden JD, Harrod MJ et al (1974) Familial incomplete hermaphroditism, type 2. Decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias. N Engl J Med 291(18):944-949
8. McConnell JD, Bruskewitz R, Walsh P et al (1998) The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 338(9):557-563
9. Roehrborn CG, Boyle P, Bergner D et al (1999) Serum prostate-specific antigen and prostate volume predict long-term outcome in symptoms and flow rate: Results of a 4-year, randomized trial comparing finasteride vs. placebo. PLESS Study Group. Urology 54(4):662-669
10. Boyle P, Gould AL, Roehrborn CG (1996) Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 48:398-405
11. Roehrborn CG, McConnell J, Bonilla J et al (2000) For the proscar long-term efficacy and safety study: Serum PSA concentration is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. J Urol 163:13-20
12. Roehrborn CG, McConnell J, Lieber M et al (1999) For the PLESS study group. Serum prostate-specific antigen is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. Urology 53:473-480
13. Roehrborn CG, Boyle P, Nickel JC et al (2002) Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 60(3):434-441
14. Roehrborn CG, Boyle P, Bergner D et al (1999) Serum prostate-specific antigen and prostate volume predict long-term outcome in symptoms and flow rate: Results of a 4-year, randomized trial comparing finasteride vs. placebo. PLESS Study Group. Urology 54(4):662-669
15. Boyle P, Siami P, Wachs BH et al (2002) Effect of dutasteride on the risk of acute urinary retention and the need for surgical treatment [abstract 1479]. J Urol 167(suppl 4):372
16. Donohue JF, Hayne D, Karnik U, Thomas DR, Foster MC (2005) Randomized, placebo-controlled trial showing that finasteride reduces prostatic vascularity rapidly within 2 weeks. BJU Int 96(9):1319-1322
17. Pareek G, Shevchuk M, Armenakas NA, Vasjovic L, Hochberg DA, Basillote JB, Fracchia JA (2003) The effect of finasteride on the expression of vascular endothelial growth factor and microvessel density: A possible mechanism for decreased prostatic bleeding in treated patients. J Urol 169(1):20-23
18. Peters TJ, Donovan JL, Kay HE, Abrams P, de la Rosette JJMCH, Porru D et al (1997) The international continence society benign prostatic hyperplasia study: The bothersomeness of urinary symptoms. J Urol 157:885
19. Hyman MJ, Groutz A, Blaivas JG (2001) Detrusor instability in men: correlation of lower urinary tract symptoms with urodynamic findings. J Urol 166:550
20. Kaplan SA, Walmsley K, Te AE (2005) Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 174:2273-2276
21. Schiff JD, Mulhall JP (2004) The link between LUTS and ED: Clinical and basic science evidence. J Androl 24(4):470-478
22. Hopps CV, Mulhall JP (2003) Assessment of the impact of sildenafil citrate on lower urinary tract symptoms (LUTS) in men with erectile dysfunction (ED). Abstract #1401. J Urol 169(4):106
23. McConnell JD, Roehrborn CG, Bautista AM et al (2003) For the MTOPS research group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. NEJM 285-296
24. Lepor H, Williford WO, Barry MJ et al (1996) For the veterans affairs cooperative studies benign prostatic hyperplasia study group: The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med 335:533-539
25. Kaplan SA, McConnell JD, Roehrborn CG, Meehan AG, Lee MW, Noble WR, Kusek JW, Nyberg LM (2006) Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater. J Urol 175:217-221
26. Larson TR (2002) Rationale and assessment of minimally invasive approaches to benign prostatic hyperplasia therapy. Urology 59(suppl 1):12-16
27. Larson TR, Bostwick DG, Corica A (1996) Temperature-correlated histopathologic changes following microwave thermoablation of obstructive tissue in patients with benign prostatic hyperplasia. Urology 47:463-69
28. Floratos DL, Kiemeney LA, Rossi L et al (2001) Long-term follow-up of randomized transurethral microwave thermotherapy versus transurethral prostatic resection study. J Urol 165:1533-1538
29. Bruskewitz R, Issa MM, Roehrborn CG et al (1998) A prospective, randomized 1-year clinical trial comparing transurethral needle ablation to transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia. J Urol 159:1588-1593
30. Norby B, Nielsen HV, Frimodt-Moller PC (2002) Transurethral interstitial laser coagulation of the prostate and transurethral microwave thermotherapy vs transurethral resection or incision of the prostate: results of a randomized, controlled study in patients with symptomatic benign prostatic hyperplasia. BJU Int 90(9):853-862
31. Gonzalez RR, Te AE (2003) How do transurethral needle ablation of the prostate and transurethral microwave thermotherapy compare with transurethral prostatectomy? Curr Urol Rep 4:297-306
32. Roehrborn CG, Burkhard FC, Bruskewitz RC et al (1999) The effects of transurethral needle ablation and resection of the prostate on pressure flow urodynamics parameters: Analysis of the Unites States randomized study. J Urol 162:92-97
33. Gupta N, Sivaramakrishna, Kumar R, Dogra PN, Seth A (2006) Comparison of standard transurethral resection, transurethral vapour resection and holmium laser enucleation of the prostate for managing benign prostatic hyperplasia of > 40g. BJU Int 97(1):85-89
34. Kuntz RM, Lehrich K (2002) Transurethral holmium laser enucleation versus transvesical open enucleation for prostate adenoma greater than 100 gm.: A randomized prospective trial of 120 patients. J Urol 168(4 Pt 1):1465-1469
35. Te A, Malloy TR, Stein BS, Ulchake JC, Nseyo UO, Mahmood AH, Malek RS (2004) Photoselective vaporization of the prostate for the treatment of benign prostatic hyperplasia: 12-month results from the first United States multicenter prospective trial. J Urol 172:1404-1408
36. Sandhu JS, Ng C, VanderBrink BA, Egan E, Kaplan SA, Te AE (2004) High power potassium-titanyl-phosphate (KTP) photoselective laser vaporization of the prostate (PVP) for the treatment of benign prostatic hyperplasia (BPH) in men with large prostates. Urology 64:1155-1159
37. Sandhu JS, Nb CK, Gonzalez RR, Kaplan SA, Te AE (2005) Photoselective laser vaporization prostatectomy in men receiving anticoagulants. J Endourol 19(10):1196-1198